Crossmark

Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site

Crossref DOI link: https://doi.org/10.1186/s40425-019-0644-7

Published Online: 2019-07-10

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lopes, Alessandra

Feola, Sara

Ligot, Sophie

Fusciello, Manlio

Vandermeulen, Gaëlle

Préat, Véronique

Cerullo, Vincenzo https://orcid.org/0000-0003-4901-3796
Funding

Funding for this research was provided by:

European Research Council (681219)

Jane ja Aatos Erkon Säätiö (3292-3d570)

FIRTS Spin-off (1610437)
License Information

Text and Data Mining valid from 2019-07-10
More Information

Article History

Received: 25 January 2019

Accepted: 19 June 2019

First Online: 10 July 2019

Ethics approval and consent to participate

: All animal experiments were reviewed and approved by the Experimental Animal Committee of the University of Helsinki and the Provincial Government of Southern Finland and the Belgian national regulations guidelines in accordance with EU Directive 2010/63/EU.

: Not applicable.

: V.C. is cofounder and shareholder of Valo Therapeutics.